Last edition
News about "microsphere drug delivery "
Samsung Bioepis and Epis NexLab Partner G2GBIO to Develop Long-Acting Semaglutide
Samsung Bioepis and Epis NexLab have signed a research collaboration and licensing agreement with G2GBIO to develop novel assets, including long-acting semaglutide, using G2GBIO’s proprietary microsphere drug delivery technology.
Microsphere Drug Delivery | 16/03/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members